Constructing A Nomogram Prediction Model for Active Pulmonary Tuberculosis Based on AAT and Cytokines
-
摘要:
目的 构建AAT及细胞因子在活动性肺结核诊断中的预测模型。 方法 收集昆明市第三人民医院2020年3月至2021年3月收治的96例活动性肺结核患者作为实验组,选择同期82例健康体检者为对照组,比较2组HAP、CRP、AAT及细胞因子水平的差异,基于 Logistic回归分析分析结果,构建Nomogram预测模型,并对模型进行验证与评价。 结果 多因素Logistic回归分析显示,AAT(OR = 0.983,95%CI = 0.968~0.999,P = 0.039),IFN-γ(OR = 0.783,95%CI = 0.659~0.931,P = 0.006),TNF-α(OR = 1.495,95%CI = 1.106~2.020,P = 0.009)均是活动性肺结核的预测因子(P < 0.05)。 结论 该模型拟合度、ROC曲线下面积均良好,证实该模型有较高的预测准确率。基于上述预测因子建立的Nomogram模型具有良好的预测效能,可为活动性肺结核的实验室诊断提供一定的参考价值。 -
关键词:
- 活动性肺结核 /
- 预测因子 /
- Nomogram模型
Abstract:Objective To construct a predictive model of AAT and cytokines in the diagnosis of active pulmonary tuberculosis. Methods A total of 96 patients with active pulmonary tuberculosis admitted to the Third People’s Hospital of Kunming from March 2020 to March 2021 were collected as the experimental group, and 82 healthy subjects during the same period were selected as the control group. HAP, CRP, AAT and cytokines were compared between the two groups. Based on the results of Logistic regression analysis, a Nomogram prediction model was constructed, and the model was verified and evaluated. Results Multivariate logistic regression analysis showed that AAT (OR = 0.983, 95% CI = 0.968-0.999, P = 0.039), IFN-γ (OR = 0.783, 95% CI = 0.659-0.931, P = 0.006), TNF-α (OR = 1.495, 95% CI = 1.106-2.020, P = 0.009) are predictors of active pulmonary tuberculosis (P < 0.05). Conclusion The fit of the model and the area under the ROC curve were good, which confirmed that the model had a high prediction accuracy. The Nomogram model established based on the above predictors has good predictive performance and can provide a certain reference value for the laboratory diagnosis of active pulmonary tuberculosis. -
Key words:
- Active pulmonary tuberculosis /
- Predictors /
- Nomogram model
-
表 1 活动性肺结核患者指标的单因素分析 [( $\bar x \pm s $)/M(P25,P75)]
Table 1. Univariate analysis of indicators in patients with active tuberculosis [( $\bar x \pm s $)/M(P25,P75)]
项目 实验组(n = 96) 对照组(n = 82) Z/t P IgG(g/L) 13.88±4.84 12.77±3.66 1.728 0.086 IgA(g/L) 2.05(1.49,2.79) 1.68(1.04,2.59) 5.776 0.016 IgM(g/L) 0.94(0.64,1.39) 1.07(0.78,1.44) 2.383 0.123 HAP(mg/dL) 186.4(89.15,247.80) 101.30(57.23,185.98) 15.315 < 0.001 ** AGP(mg/dL) 76.10(46.95,122.00) 50.75(31.90,79.68) 16.289 < 0.001 ** AAT(mg/dL) 157.25(127.23,199.78) 126.50(114.98,153.05) 22.266 < 0.001 ** IL-1(pg/mL) 1.51(0.59,2.72) 1.74(0.98,3.54) 2.556 0.110 IL-2(pg/mL) 0.93(0.37,1.45) 1.13(0.53,1.90) 2.917 0.088 IL-4(pg/mL) 1.02(0.07,1.55) 1.22(0.28,1.74) 1.478 0.224 IL-5(pg/mL) 1.07(0.42,1.38) 1.12(0.36,1.47) 0.399 0.528 IL-6(pg/mL) 9.65(4.89,33.25) 5.12(3.18,11.06) 13.899 < 0.001 ** IL-8(pg/mL) 35.56(16.03,103.73) 53.05(16.16,132.35) 1.679 0.195 IL-10(pg/mL) 3.33(2.30,4.62) 3.33(2.14,4.24) 0.071 0.789 IL-12p70(pg/mL) 1.59(0.89,2.50) 1.88(1.17,2.72) 2.669 0.102 IL-17(pg/mL) 8.71(2.90,17.29) 10.93(4.89,23.63) 0.828 0.363 IFN-γ 3.14(1.77,6.98) 1.85(1.19,4.04) 10.587 0.001** IFN-α 2.74(2.00,60.79) 4.18(2.31,117.19) 2.140 0.144 TNF-α 1.49(1.07,2.11) 1.73(1.34,2.46) 5.651 0.017* CD3 1047.00(799.17,1414.01) 1172.83(845.90,1587.48) 2.674 0.102 CD4 583.54(426.01,775.04) 684.26(499.48,900.72) 4.577 0.032* CD8 380.88(245.90,568.90) 421.57(277.89,653.99) 0.948 0.330 CD4+/CD8+ 1.46(0.99,2.23) 1.68(1.14,2.17) 0.949 0.330 CD45+ 1394.00(883.07,1865.04) 1576.43(1094.84,2182.21) 3.227 0.072 B-cell 162.64(67.11,263.35) 206.26(103.51,315.40) 1.374 0.241 NK-cell 131.99(70.04,233.90) 192.74(125.83,285.46) 8.112 0.004* CRP 17.05(4.22,27.76) 2.74(1.18,10.69) 21.797 < 0.001 ** 与对照组相比,*P < 0.05, **P < 0.01。 表 2 发生活动性肺结核危险因素及其赋值
Table 2. Risk factors for developing active pulmonary tuberculosis and their value assignments
因素 变量名 赋值 活动性肺结核患者 X1 0 = 是;1 = 否 IgA X2 实际数值 HAP X3 实际数值 AGP X4 实际数值 AAT X5 实际数值 IL-6 X6 实际数值 IFN-γ X7 实际数值 TNF-α X8 实际数值 CD4 X9 实际数值 NK-cell X10 实际数值 CRP X11 实际数值 表 3 活动性肺结核患者指标的多因素Logistic回归分析
Table 3. Multivariate logistic regression analysis of indicators in patients with active tuberculosis
预测因子 β S.E. Wald 自由度 P OR 95%CI IgA −0.013 0.142 0.009 1 0.925 0.987 0.747~1.304 HAP −0.005 0.003 2.165 1 0.141 0.995 0.989~1.002 AGP 0.013 0.009 2.377 1 0.123 1.013 0.996~1.031 AAT −0.017 0.008 4.243 1 0.039* 0.983 0.968~0.999 IL-6 0.000 0.000 2.735 1 0.098 1.000 1.000~1.001 IFN-γ −0.244 0.088 7.641 1 0.006** 0.783 0.659~0.931 TNF-α 0.402 0.154 6.857 1 0.009** 1.495 1.106~2.020 CD4 0.000 0.001 0.246 1 0.620 1.000 0.999~1.001 NK-cell 0.000 0.001 0.010 1 0.920 1.000 0.998~1.003 CRP 0.001 0.011 0.003 1 0.959 1.001 0.979~1.022 常量 1.975 1.061 3.462 1 0.063 7.206 − 与对照组相比,*P < 0.05, **P < 0.01。 -
[1] 邓国防,路希维. 肺结核活动性判断规范及临床应用专家共识[J]. 中国防痨杂志,2020,42(4):301-307. doi: 10.3969/j.issn.1000-6621.2020.04.001 [2] 毛佳斌,孙培英,徐金田. 初治肺结核患者药物性肝损伤的危险因素分析及对策[J]. 中华全科医学,2016,14(11):1867-1869. doi: 10.16766/j.cnki.issn.1674-4152.2016.11.024 [3] Zhang Q,Wu Z,Zhang Z,et al. Efficacy and effect of free treatment on multidrug-resistant tuberculosis[J]. Exp Ther Med,2016,11(3):777-782. doi: 10.3892/etm.2015.2966 [4] 路希伟,伍建林,张国庆,等. 涂阴、涂阳活动性肺结核CT征象的对照研究[J]. 中国医学影像技术,2007,23(9):1337-1341. doi: 10.3321/j.issn:1003-3289.2007.09.021 [5] 温保江,陈栋军,志勇,等. 不同检测方法对肺结核诊断价值的分析[J]. 结核病与肺部健康杂志,2018,7(2):133-136. [6] Wu Y B,Ye Z J,Qin S M,et al. Combined detections of interleukin 27,interferon-γ,and adenosine deaminase in pleural effusion for diagnosis of tuberculous pleurisy[J]. Chin Med J,2013,126(17):3215-3221. [7] Han M,Xiao H,Yan L. Diagnostic performance of nucleic acid tests in tuberculous pleurisy[J]. BMC Infect Dis,2020,20(1):242. doi: 10.1186/s12879-020-04974-z [8] Vasil’Eva E V,Verbov V N,Ivanovskii V B,et al. Combined determination of spontaneous and antigen-induced production of cytokines for differential diagnostics of active tuberculosis of lungs and latent tuberculosis infection[J]. Zhurnal Mikrobiologii Epidemiologii I Immunobiologii,2013,4(4):77-85. [9] Zellweger J P,Sotgiu G,Corradi M,et al. The diagnosis of latent tuberculosis infection (LTBI):Currently available tests,future developments,and perspectives to eliminate tuberculosis (TB)[J]. Med Lav,2020,111(3):170-183. [10] 侯杏芳,孟娟,张国良,等. 肺结核患者外周血单个核细胞中miRNA-150的表达及意义[J]. 临床肺科杂志,2016,21(3):501-504. doi: 10.3969/j.issn.1009-6663.2016.03.033 [11] 中华人民共和国国家卫生和计划生育委员会. 肺结核诊断标准(WS 288—2017)[J]. 新发传染病电子杂志,2018,3(1):59-61. doi: 10.3877/j.issn.2096-2738.2018.01.017 [12] Halliday A,Masonou T,Tolosa-Wright M,et al. Immunodiagnosis of active tuberculosis[J]. Expert Rev Respir Med,2019,13(6):521-532. doi: 10.1080/17476348.2019.1615888 [13] 陈科帆,熊域皎,焦家欢,等. CD44及相关细胞因子水平对活动性肺结核诊断及预后评估价值[J]. 中国防痨杂志,2021,43(5):513-515. doi: 10.3969/j.issn.1000-6621.2021.05.018 [14] 陈志,林明贵,梁建琴,等. 活动性肺结核患者血清炎性因子变化特点及与免疫状态的关系[J]. 第三军医大学学报,2006,28(11):1234-1236. doi: 10.3321/j.issn:1000-5404.2006.11.034 [15] 程静,马乐,苏春芳. 活动性肺结核患者肺泡灌洗液中细胞因子的水平变化及意义[J]. 广东医学,2016,37(3):415-417. doi: 10.13820/j.cnki.gdyx.2016.03.027 [16] 牛文一,李明瑛,万勇敢. 活动性肺结核患者外周血CD4~+T细胞中TLR4与血清IFN-γ、IL-4的关系[J]. 临床肺科杂志,2018,23(8):1509-1512. doi: 10.3969/j.issn.1009-6663.2018.08.040 [17] 黄德东,刘庭贵,张云,等. γ-干扰素释放试验在活动性肺结核诊断中的价值[J]. 中华肺部疾病杂志(电子版),2020,13(3):329-333. doi: 10.3877/cma.j.issn.1674-6902.2020.03.008 [18] 许敏殷,刘银,刘丽蓉,等. γ干扰素释放试验联合IL-6检测对活动性肺结核的诊断价值[J]. 中国现代医学杂志,2020,30(10):18-21. doi: 10.3969/j.issn.1005-8982.2020.10.004 [19] 郑梓坤,谢舒颖,陈为铠,等. CD_3~+、CD_4~+细胞亚群与细胞因子IL-17水平在活动性肺结核治疗转归中的诊断价值[J]. 华夏医学,2020,33(1):7-10. [20] Cardona P J. Pathogenesis of tuberculosis and other mycobacteriosis[J]. Enferm Infecc Microbiol Clin (Engl Ed),2018,36(1):38-46. doi: 10.1016/j.eimc.2017.10.015 [21] 陈超蕾,林雨婷,张桑桑,等. GPC3-WNT-JNK通路介导脂多糖诱导肺局部细胞炎症[J]. 温州医科大学学报,2019,49(10):703-711. doi: 10.3969/j.issn.2095-9400.2019.10.001 [22] Su W L,Perng W C,Huang C H,et al. Association of reduced tumor necrosis factoralpha,gamma interferon,and interleukin-1beta (IL-1beta) but increased IL-10 expression with improved chest radiography in patients with pulmonary tuberculosis[J]. Clin Vaccine Immunol,2010,17(2):223-231. doi: 10.1128/CVI.00381-09 [23] Mily A,Sarker P,Taznin I,et al. Slow radiological improvement and persistent low-grade inflammation after chemotherapy in tuberculosis patients with type 2 diabetes[J]. BMC Infect Dis,2020,20(1):933. doi: 10.1186/s12879-020-05473-x [24] 中华医学会结核病学分会. 结核分枝杆菌γ-干扰素释放试验及临床应用专家意见(2021年版)[J]. 中华结核和呼吸杂志,2022,45(2):143-150. doi: 10.3760/cma.j.cn112147-20211110-00794 [25] Suzukawa M,Takeda K,Akashi S,et al. Evaluation of cytokine levels using quantiFERON-TB gold plus in patients with active tuberculosis[J]. J Infect,2020,80(5):547-553. doi: 10.1016/j.jinf.2020.02.007 [26] 赵鸿鹏,路希维. 影像学检查在肺结核诊治中的应用现状与展望[J]. 结核病与肺部健康杂志,2019,8(1):5-8.